{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:19:25Z","timestamp":1787570365124,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00120-026-02900-w","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:25:12Z","timestamp":1785482712000},"page":"999-1007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Therapie des muskelinvasiven Harnblasenkarzinoms","Perioperative treatment of muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"65","author":[{"given":"G\u00fcnter","family":"Niegisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Grunewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"3","key":"2900_CR1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2012.05.048","volume":"62","author":"JJ Meeks","year":"2012","unstructured":"Meeks\u00a0JJ, Bellmunt\u00a0J, Bochner\u00a0BH, Clarke\u00a0NW, Daneshmand\u00a0S, Galsky\u00a0MD, Hahn\u00a0NM, Lerner\u00a0SP, Mason\u00a0M, Powles\u00a0T, Sternberg\u00a0CN, Sonpavde\u00a0G (2012) A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol Oncol 62(3):523\u2013533. https:\/\/doi.org\/10.1016\/j.eururo.2012.05.048","journal-title":"European urology"},{"issue":"12","key":"2900_CR2","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00120-022-01870-z","volume":"61","author":"CH Ohlmann","year":"2022","unstructured":"Ohlmann\u00a0CH, Kerkmann\u00a0M, Holtmann\u00a0L, Gschwend\u00a0JE, Retz\u00a0M, de Wit\u00a0M (2022) Quality assurance for the treatment of muscle-invasive and metastasized bladder carcinoma in Germany : An initiative of the Working Groups Urological Oncology (AUO) and Internal Oncology (AIO) in the German Cancer Society (DKG). Urologie 61(12):1351\u20131364. https:\/\/doi.org\/10.1007\/s00120-022-01870-z","journal-title":"Urologie"},{"issue":"3","key":"2900_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000536321","volume":"108","author":"MJ Reike","year":"2024","unstructured":"Reike\u00a0MJ, Reicherz\u00a0A, Tully\u00a0KH, Bahlburg\u00a0H, Maas\u00a0M, Bach\u00a0P, Klumper\u00a0N, Eckstein\u00a0M, Hartmann\u00a0A, Breyer\u00a0J, Erben\u00a0P, Bolenz\u00a0C, Noldus\u00a0J, Berg\u00a0S, Roghmann\u00a0F (2024) An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder Cancer. Urologia internationalis 108(3):183\u2013189. https:\/\/doi.org\/10.1159\/000536321","journal-title":"Urologia internationalis"},{"key":"2900_CR4","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2025) S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 3.0. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/harnblasenkarzinom. Zugegriffen: .9.2025"},{"issue":"19","key":"2900_CR5","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T, Catto\u00a0JWF, Galsky\u00a0MD, Al-Ahmadie\u00a0H, Meeks\u00a0JJ, Nishiyama\u00a0H, Vu\u00a0TQ, Antonuzzo\u00a0L, Wiechno\u00a0P, Atduev\u00a0V, Kann\u00a0AG, Kim\u00a0TH, Suarez\u00a0C, Chang\u00a0CH, Roghmann\u00a0F, Ozguroglu\u00a0M, Eigl\u00a0BJ, Oliveira\u00a0N, Buchler\u00a0T, Gadot\u00a0M, Zakharia\u00a0Y, Armstrong\u00a0J, Gupta\u00a0A, Hois\u00a0S, van der Heijden\u00a0MS, Investigators N (2024) Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med 391(19):1773\u20131786. https:\/\/doi.org\/10.1056\/NEJMoa2408154","journal-title":"N Engl J Med"},{"issue":"6","key":"2900_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102176","volume":"22","author":"R O\u2019Dwyer","year":"2024","unstructured":"O\u2019Dwyer\u00a0R, Musat\u00a0MG, Gulas\u00a0I, Hubscher\u00a0E, Moradian\u00a0H, Guenther\u00a0S, Kearney\u00a0M, Sridhar\u00a0SS (2024) Split-Dose Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Literature Review and Network Meta-Analysis. Clin Genitourin Cancer 22(6):102176. https:\/\/doi.org\/10.1016\/j.clgc.2024.102176","journal-title":"Clinical genitourinary cancer"},{"issue":"6","key":"2900_CR7","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.juro.2017.06.020","volume":"198","author":"B Kiss","year":"2017","unstructured":"Kiss\u00a0B, Furrer\u00a0MA, Wuethrich\u00a0PY, Burkhard\u00a0FC, Thalmann\u00a0GN, Roth\u00a0B (2017) Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence. The Journal of urology 198(6):1263\u20131268. https:\/\/doi.org\/10.1016\/j.juro.2017.06.020","journal-title":"The Journal of urology"},{"issue":"1","key":"2900_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-6620-2","volume":"20","author":"MC Hupe","year":"2020","unstructured":"Hupe\u00a0MC, Dormayer\u00a0L, Ozimek\u00a0T, Struck\u00a0JP, Hennig\u00a0MJP, Klee\u00a0M, von Klot\u00a0CAJ, Kuczyk\u00a0MA, Merseburger\u00a0AS, Kramer\u00a0MW (2020) Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer. BMC Cancer 20(1):140. https:\/\/doi.org\/10.1186\/s12885-020-6620-2","journal-title":"BMC cancer"},{"issue":"6","key":"2900_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102241","volume":"22","author":"P Scilipoti","year":"2024","unstructured":"Scilipoti\u00a0P, Moschini\u00a0M, de Angelis\u00a0M, Longoni\u00a0M, Afferi\u00a0L, Lonati\u00a0C, Zaurito\u00a0P, Pichler\u00a0R, Necchi\u00a0A, Montorsi\u00a0F, Briganti\u00a0A, Mari\u00a0A, Krajewski\u00a0W, Laukthina\u00a0E, Pradere\u00a0B, Giudice\u00a0FD, Mertens\u00a0L, Gallioli\u00a0A, Soria\u00a0F, Gontero\u00a0P, Albisinni\u00a0S, Shariat\u00a0SF, Carando\u00a0R, European Association of Urology - Young Academic Urologists Ucwg (2024) Risk of Metachronous Upper Tract Urothelial Carcinoma After Ureteral Stenting in Patients With Bladder Cancer. Clin Genitourin Cancer 22(6):102241. https:\/\/doi.org\/10.1016\/j.clgc.2024.102241","journal-title":"Clinical genitourinary cancer"},{"key":"2900_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247721","author":"Y Kim","year":"2023","unstructured":"Kim\u00a0Y, Oh\u00a0CH, Choi\u00a0SL, Kim\u00a0S (2023) Percutaneous Ureteral Stent Insertion in Patients with Benign Uretero-Ileal Anastomosis Strictures Who Underwent Radical Cystectomy: Assessing Risk Factors for Stent Patency. J\u00a0Clin Med. https:\/\/doi.org\/10.3390\/jcm12247721","journal-title":"J Clin Med"},{"key":"2900_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00761-022-01217-5","author":"G von Amsberg","year":"2022","unstructured":"von Amsberg\u00a0G, Retz\u00a0M, De Santis\u00a0M, Niegisch\u00a0G, Interdisziplin\u00e4re Arbeitsgruppe HarnblasenCarcinom DKD (2022) Erstlinientherapie des metastasierten Urothelkarzinoms: ein Update. Onkologie. https:\/\/doi.org\/10.1007\/s00761-022-01217-5","journal-title":"Die Onkologie"},{"key":"2900_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511674","author":"C Vulsteke","year":"2026","unstructured":"Vulsteke\u00a0C, Adra\u00a0N, Danchaivijitr\u00a0P, Sabadash\u00a0M, Rodriguez-Vida\u00a0A, Zhang\u00a0Z, Atduev\u00a0V, Goger\u00a0YE, Rausch\u00a0S, Kang\u00a0SH, Loriot\u00a0Y, Bedke\u00a0J, Galsky\u00a0MD, O\u2019Donnell\u00a0PH, von Amsberg\u00a0G, Alimohamed\u00a0N, Sulimka\u00a0G, Gupta\u00a0S, Paramonov\u00a0V, Nakane\u00a0K, Mihm\u00a0M, Meng\u00a0C, Huang\u00a0CD, Ramamurthy\u00a0C, Homet Moreno\u00a0B, Ullen\u00a0A, Investigators\u00a0KE (2026) Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2511674","journal-title":"N Engl J Med"},{"issue":"2 Pt 1","key":"2900_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/01.ju.0000090967.08622.33","volume":"171","author":"E Winquist","year":"2004","unstructured":"Winquist\u00a0E, Kirchner\u00a0TS, Segal\u00a0R, Chin\u00a0J, Lukka\u00a0H (2004) Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a\u00a0systematic review and meta-analysis. J\u00a0Urol 171(2 Pt 1):561\u2013569. https:\/\/doi.org\/10.1097\/01.ju.0000090967.08622.33","journal-title":"J Urol"},{"issue":"2","key":"2900_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","volume":"48","author":"ABC-Meta-analysis-Collaboration","year":"2005","unstructured":"ABC-Meta-analysis-Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a\u00a0systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol Oncol 48(2):202\u2013205. https:\/\/doi.org\/10.1016\/j.eururo.2005.04.006","journal-title":"Eur Urol"},{"issue":"9373","key":"2900_CR15","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","volume":"361","author":"ABC-Meta-analysis-Collaboration","year":"2003","unstructured":"ABC-Meta-analysis-Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a\u00a0systematic review and meta-analysis. Lancet 361(9373):1927\u20131934. https:\/\/doi.org\/10.1016\/S0140-6736(03)13580-5","journal-title":"Lancet"},{"issue":"6","key":"2900_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","volume":"21","author":"M Yin","year":"2016","unstructured":"Yin\u00a0M, Joshi\u00a0M, Meijer\u00a0RP, Glantz\u00a0M, Holder\u00a0S, Harvey\u00a0HA, Kaag\u00a0M, Fransen van de Putte\u00a0EE, Horenblas\u00a0S, Drabick\u00a0JJ (2016) Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. The oncologist 21(6):708\u2013715. https:\/\/doi.org\/10.1634\/theoncologist.2015-0440","journal-title":"The oncologist"},{"issue":"18","key":"2900_CR17","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.21.02051","volume":"40","author":"C Pfister","year":"2022","unstructured":"Pfister\u00a0C, Gravis\u00a0G, Flechon\u00a0A, Chevreau\u00a0C, Mahammedi\u00a0H, Laguerre\u00a0B, Guillot\u00a0A, Joly\u00a0F, Soulie\u00a0M, Allory\u00a0Y, Harter\u00a0V, Culine\u00a0S, Investigators VT (2022) Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. J\u00a0Clin Oncol 40(18):2013\u20132022. https:\/\/doi.org\/10.1200\/JCO.21.02051","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"22","key":"2900_CR18","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin\u00a0DF, Witjes\u00a0JA, Gschwend\u00a0JE, Schenker\u00a0M, Valderrama\u00a0BP, Tomita\u00a0Y, Bamias\u00a0A, Lebret\u00a0T, Shariat\u00a0SF, Park\u00a0SH, Ye\u00a0D, Agerbaek\u00a0M, Enting\u00a0D, McDermott\u00a0R, Gajate\u00a0P, Peer\u00a0A, Milowsky\u00a0MI, Nosov\u00a0A, Neif\u00a0A Jr., Tupikowski\u00a0K, Toms\u00a0L, Fischer\u00a0BS, Qureshi\u00a0A, Collette\u00a0S, Unsal-Kacmaz\u00a0K, Broughton\u00a0E, Zardavas\u00a0D, Koon\u00a0HB, Galsky\u00a0MD (2021) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 384(22):2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442","journal-title":"N Engl J Med"},{"issue":"1","key":"2900_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.24.00340","volume":"43","author":"MD Galsky","year":"2025","unstructured":"Galsky\u00a0MD, Witjes\u00a0JA, Gschwend\u00a0JE, Milowsky\u00a0MI, Schenker\u00a0M, Valderrama\u00a0BP, Tomita\u00a0Y, Bamias\u00a0A, Lebret\u00a0T, Shariat\u00a0SF, Park\u00a0SH, Agerbaek\u00a0M, Jha\u00a0G, Stenner\u00a0F, Ye\u00a0D, Giudici\u00a0F, Dutta\u00a0S, Askelson\u00a0M, Nasroulah\u00a0F, Zhang\u00a0J, Brophy\u00a0L, Bajorin\u00a0DF (2025) Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274. J\u00a0Clin Oncol 43(1):15\u201321. https:\/\/doi.org\/10.1200\/JCO.24.00340","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"2900_CR20","doi-asserted-by":"crossref","unstructured":"Galsky MD, Valderrama BP, Maruzzo M, Pous AF, Ciuleanu T\u2011E, Chatzkel JA, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Wirtz H, Mihm M, Huang Q, Rogiers J, Moreno BH, Lista AGDL (2026) Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase\u00a03 KEYNOTE-B15 study. Journal of Clinical Oncology 44 (7_suppl):LBA630-LBA630. https:\/\/doi.org\/10.1200\/JCO.2026.44.7_suppl.LBA630","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02900-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02900-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02900-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:22:45Z","timestamp":1787566965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02900-w"}},"subtitle":["Aktuelle Behandlungskonzepte","Current treatment concepts"],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2900"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02900-w","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Niegisch\n                      : A. Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Deutsche Forschungsgemeinschaft, Leitlinienprogramm Onkologie, Wilhelm-Sander-Stiftung. \u2013 Vortr\u00e4ge, Symposien: Roche Pharma, MEDAC, Pfizer, BMS, AstraZeneca, Merck, Johnson &amp; Johnson, Astellas, medudy, medtoday, FOMF, solution Akademie; Kongressunterst\u00fctzung: Roche Pharma, Pfizer, Merck, Johnson &amp; Johnson, Ipsen. \u2013 Advisory Boards: Roche Pharma, Sanofi, BMS, Merck Serono, Pfizer, MEDAC, Ipsen, Johnson &amp; Johnson, Astellas, AstraZeneca, Novartis, MEDAC. \u2013 B. Nichtfinanzielle Interessen: Angestellter Urologe, Klinik f\u00fcr Urologie, Universit\u00e4tsklinikum und Medizinische Fakult\u00e4t, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf; stellv. Direktor, Centrum f\u00fcr Integrierte Onkologie (CIO) D\u00fcsseldorf, CIO Aachen-Bonn-K\u00f6ln-D\u00fcsseldorf (ABCD), D\u00fcsseldorf | DKG: AUO - Vorstandsmitglied, Sprecher Peniskarzinom, IABC - Sprecher | Mitgliedschaften: DGU, AK urologische Forschung, NRWGU, EACR, EAU, ASCO | CIO D\u00fcsseldorf - stellv. Direktor | Off-Label-Kommission des BFarm - Mitglied, S3 Harnblasenkarzinom - Koordinator.\n                      C.\u00a0M.\u00a0Grunewald\n                      : A. Finanzielle Interessen: Referent: Astra Zeneca. \u2013 B. Nichtfinanzielle Interessen: Angestellte Urologin Uniklinik D\u00fcsseldorf.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}